Innovation Pharmaceuticals Inc (IPIX)

[Roger 2]

What if delayed-release Brilacidin Tablets (see company release) could be shown appropriate and successful in and for intestinal delivery, decimating the Covid-19 cells on contact (being able to target specific section of intestine)...would it not be important? (assuming success in second RBL trial)

Yes, if Covid-19 is susceptible to Brilacidin targeting specific out breaks in the body would be a positive quality. Even more so if a localized colony could be discovered prior to intrabody viral spread. However we're a long way from developing the testing that would be needed to pin down colonies during incubation.

If B works against Covid 19, I'd expect trials to determine the most effective route of administration.

As the virus seems to have an affinity for smooth cell wall organs in general a rapid systemic delivery might be preferable.

If B's bio-availability from intestinal absorption is close to and longer lasting than an IV infusion IMO a case could be made for an initial virucidal IV treatment followed by a sustained PO regimen of Extended Release capsule/tablets.

It will be interesting to find out how local direct delivery systems(time release and/or inhalants) fare in the future.